Hydroxyurea for hemoglobin E/β-thalassemia: a systematic review and meta-analysis

Area of Science:

• Hematology
• Genetics
• Pharmacology

Background:

• Hemoglobin E-beta thalassemia (Hb E/β-thalassemia) presents significant clinical variability, chronic anemia, and complications from ineffective erythropoiesis and iron overload.
• Hydroxyurea (HU) is an oral chemotherapeutic agent with potential to mitigate disease severity in β-thalassemia variants.

Purpose of the Study:

• To evaluate the clinical efficacy and safety of Hydroxyurea (HU) in patients diagnosed with Hb E/β-thalassemia.
• To synthesize existing evidence on HU's impact on disease parameters and adverse events in this specific patient population.

Main Methods:

• A systematic literature search was conducted across major databases (MEDLINE, EMBASE, Cochrane) and conference proceedings.
• Included studies were assessed for quality using NIH tools, with effect size calculated as a proportion of responders.
• A meta-analysis was performed on data from one RCT and four observational studies involving 106 patients.

Main Results:

• Hydroxyurea (HU) demonstrated a significant response rate of 46% in Hb E/β-thalassemia patients, with no statistical heterogeneity observed.
• The meta-analysis reported no serious adverse effects associated with HU treatment in the included studies.
• Preliminary findings suggest a potential benefit of HU in managing Hb E/β-thalassemia.

Conclusions:

• Patients with Hb E/β-thalassemia may experience clinical benefits from a trial of Hydroxyurea (HU).
• Larger randomized controlled trials (RCTs) are essential to definitively confirm HU's efficacy and evaluate long-term toxicity and response sustainability.
• Further research is warranted to establish HU as a standard treatment for Hb E/β-thalassemia.